Next Article in Journal
The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis
Next Article in Special Issue
TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
Previous Article in Journal
Exosome Biogenesis in the Protozoa Parasite Giardia lamblia: A Model of Reduced Interorganellar Crosstalk
Previous Article in Special Issue
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study
Open AccessFeature PaperArticle

Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy

Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy
Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy
Department of Biology, University of Padova, 35128 Padova, Italy
Department of Physics, University of Trento, Via Sommarive 14, 38123 Trento, Italy
Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, 00161 Roma, Italy
Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, 4000 Liège, Belgium
Author to whom correspondence should be addressed.
The authors contributed equally to this work.
Cells 2019, 8(12), 1601;
Received: 31 October 2019 / Revised: 2 December 2019 / Accepted: 6 December 2019 / Published: 9 December 2019
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Ovarian Cancer)
Anti-angiogenic therapy triggers metabolic alterations in experimental and human tumors, the best characterized being exacerbated glycolysis and lactate production. By using both Liquid Chromatography-Mass Spectrometry (LC-MS) and Nuclear Magnetic Resonance (NMR) analysis, we found that treatment of ovarian cancer xenografts with the anti-Vascular Endothelial Growth Factor (VEGF) neutralizing antibody bevacizumab caused marked alterations of the tumor lipidomic profile, including increased levels of triacylglycerols and reduced saturation of lipid chains. Moreover, transcriptome analysis uncovered up-regulation of pathways involved in lipid metabolism. These alterations were accompanied by increased accumulation of lipid droplets in tumors. This phenomenon was reproduced under hypoxic conditions in vitro, where it mainly depended from uptake of exogenous lipids and was counteracted by treatment with the Liver X Receptor (LXR)-agonist GW3965, which inhibited cancer cell viability selectively under reduced serum conditions. This multi-level analysis indicates alterations of lipid metabolism following anti-VEGF therapy in ovarian cancer xenografts and suggests that LXR-agonists might empower anti-tumor effects of bevacizumab. View Full-Text
Keywords: ovarian cancer; bevacizumab; metabolism; lipid droplets; LXR agonist ovarian cancer; bevacizumab; metabolism; lipid droplets; LXR agonist
Show Figures

Figure 1

MDPI and ACS Style

Curtarello, M.; Tognon, M.; Venturoli, C.; Silic-Benussi, M.; Grassi, A.; Verza, M.; Minuzzo, S.; Pinazza, M.; Brillo, V.; Tosi, G.; Ferrazza, R.; Guella, G.; Iorio, E.; Godfroid, A.; Sounni, N.E.; Amadori, A.; Indraccolo, S. Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. Cells 2019, 8, 1601.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop